Here's How ABT Broadens Diagnostics Growth Base With Oncology Expansion

Following the March 2026 acquisition of Exact Sciences, Diagnostics now includes the Cancer Diagnostics business. Cancer Diagnostics sales grew 13.3%, driven by mid-teens growth in Cologuard and a colorectal cancer screening test, along with contributions from precision oncology and international operations. Abbott expects Cancer Diagnostics’ growth to accelerate in the second half. This growth is expected to benefit from care gap programs, repeat screenings, newer tests and increased international adoption. 

Peer Update

Danaher Corporation DHR Diagnostics segment continued to perform strong in the second quarter, with core revenues increasing 2% year over year. Clinical diagnostics revenues grew at a mid-single-digit rate, supported by solid performance at Beckman Coulter Diagnostics and high-single-digit growth at Leica Biosystems and Radiometer. Cepheid’s non-respiratory revenues increased at a low-double-digit rate, driven by strength in hospital-acquired infection and sexual-health assays, while lower seasonal infection rates continued to pressure respiratory testing revenues. In China, declines at Beckman began to moderate as pricing stabilized and volumes improved, easing some of the pressure from volume-based procurement and reimbursement changes. 

QuidelOrtho Corporation QDEL continues to benefit from its focus on the diagnostics business, supported by healthy growth across several key areas during the second quarter. Labs revenues increased 4% as reported driven by strength in the core business, although slower sales in China related to changes in In Vitro Diagnostics pricing partially offset growth. Immunohematology revenues increased 1% with growth improving to 5% outside China. Meanwhile, Point of Care remained a notable growth driver, with revenues advancing 16%, including a 10% increase in Triage revenues, highlighting solid momentum across the company’s diagnostics portfolio.

ABT Price Performance

In the past year, Abbott shares have plunged 19.6% compared with the industry’s 25.9% decline. 

Image Source: Zacks Investment Research

Expensive Valuation

ABT currently trades at a forward 12-month Price-to-Sales (P/S) of 3.54X compared with the industry median of 2.81X.

Image Source: Zacks Investment Research

ABT Stock Estimate Trend

In the past 30 days, ABT’s EPS estimate for 2026 has moved north 0.2%.

Image Source: Zacks Investment Research

ABT stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research